IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $23.59 million. The enterprise value is $23.39 million.

Market Cap	23.59M
Enterprise Value	23.39M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, after market close.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

IGC Pharma has 79.69 million shares outstanding. The number of shares has increased by 29.68% in one year.

Current Share Class	79.69M
Shares Outstanding	79.69M
Shares Change (YoY)	+29.68%
Shares Change (QoQ)	+2.14%
Owned by Insiders (%)	9.29%
Owned by Institutions (%)	20.91%
Float	72.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	17.41
Forward PS	18.34
PB Ratio	3.70
P/TBV Ratio	5.37
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	18.92
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.04.

Current Ratio	1.15
Quick Ratio	0.21
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -115.06% and return on invested capital (ROIC) is -69.70%.

Return on Equity (ROE)	-115.06%
Return on Assets (ROA)	-54.70%
Return on Invested Capital (ROIC)	-69.70%
Return on Capital Employed (ROCE)	-138.61%
Revenue Per Employee	$18,448
Profits Per Employee	-$131,478
Employee Count	67
Asset Turnover	0.12
Inventory Turnover	0.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.44% in the last 52 weeks. The beta is 1.32, so IGC Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.32
52-Week Price Change	+1.44%
50-Day Moving Average	0.34
200-Day Moving Average	0.40
Relative Strength Index (RSI)	36.90
Average Volume (20 Days)	399,875

Short Selling Information

The latest short interest is 953,232, so 1.20% of the outstanding shares have been sold short.

Short Interest	953,232
Short Previous Month	768,304
Short % of Shares Out	1.20%
Short % of Float	1.32%
Short Ratio (days to cover)	2.37

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.24 million and -$8.81 million in losses. Loss per share was -$0.12.

Revenue	1.24M
Gross Profit	636,000
Operating Income	-8.90M
Pretax Income	-13.30M
Net Income	-8.81M
EBITDA	-8.27M
EBIT	-8.90M
Loss Per Share	-$0.12

Full Income Statement

Balance Sheet

The company has $470,000 in cash and $270,000 in debt, giving a net cash position of $200,000 or $0.00 per share.

Cash & Cash Equivalents	470,000
Total Debt	270,000
Net Cash	200,000
Net Cash Per Share	$0.00
Equity (Book Value)	6.26M
Book Value Per Share	0.08
Working Capital	394,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.59 million and capital expenditures -$109,000, giving a free cash flow of -$4.70 million.

Operating Cash Flow	-4.59M
Capital Expenditures	-109,000
Free Cash Flow	-4.70M
FCF Per Share	-$0.06

Full Cash Flow Statement

Margins

Gross Margin	51.46%
Operating Margin	-720.06%
Pretax Margin	-712.70%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.68%
Shareholder Yield	-29.68%
Earnings Yield	-37.35%
FCF Yield	-19.93%

Analyst Forecast

The average price target for IGC Pharma is $3.75, which is 1,166.89% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.75
Price Target Difference	1,166.89%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Apr 19, 2013
Split Type	Reverse
Split Ratio	0.1:1

Scores

IGC Pharma has an Altman Z-Score of -15.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-15.44
Piotroski F-Score	4